Complete Accounts of Integrated Drug Discovery and Development
Oxford University Press Inc (Verlag)
978-0-8412-3432-1 (ISBN)
These engaging accounts walk readers through the drug discovery and development processes, from identification of a target compound to the development of large-scale processes. The authors hail from leading pharmaceutical companies, grounding the text in real-world applications. These accounts also touch on reaction safety and development costs, providing insight into often closed-door procedures. These relevant examples from industry are informative to chemists in
both industry and academia, especially those interested in discovering and developing drug candidates.
Jaan A. Pesti, EnginZyme AB, Stockholm, Sweden Ahmed F. Abdel-Magid, Therachem Research Medilab, LLC, Chelsea, Alabama, United States Rajappa Vaidyanathan, Bristol-Myers Squibb, Bangalore, India
Preface
Chapter 1. Synthetic Routes for Venetoclax at Different Stages of Development Yi-Yin Ku and Michael D. Wendt
Chapter 2. Discovery and Development of Lorlatinib: A Macrocyclic Inhibitor of EML4-ALK for the Treatment of NSCLC Robert Dugger, Bryan Li, and Paul Richardson
Chapter 3. From Discovery to Market Readiness: The Research and Development of the B-Sparing Phosphatidylinositol 3-Kinase Inhibitor Taselisib Remy Angelaud, Steve Staben, Timothy Heffron, Andreas Schuster, and Frederic St-Jean
Chapter 4. Discovery and Development of the First Antibody-Antibiotic Conjugate Linker-Drug Stefan G. Koenig and Thomas H. Pillow
Chapter 5. The Discovery of the Nav1.7 Inhibitor GDC-0276 and Development of an Efficient Large-Scale Synthesis Andreas Stumpf, Daniel Sutherlin, Christoph M. Dehnhardt, and Remy Angelaud
Chapter 6. Discovery and Development of AMG 333: A TRPM8 Antagonist for Migraine Neil F. Langille and Daniel B. Horne
Chapter 7. The Discovery and Chemical Development of PF-06273340: A Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor for Pain David C. Blakemore, Thomas Brandt, Craig Knight, and Sarah E. Skerratt
Chapter 8. Optimization of an Azaindazole Series of CCR1 Antagonists and Development of a Semicontinuous-Flow Synthesis Christian Harcken, Joshuaine Grant, Hossein Razavi, Maurice A. Marsini, Frederic G. Buono, Jon C. Lorenz, and Jonathan T. Reeves
Chapter 9. Discovery and Development of Non-Covalent, Reversible Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) James J. Crawford and Haiming Zhang
Chapter 10. Discovery and Early Development of Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors David W. Piotrowski and Emma L. McInturff
Chapter 11. Rational Design to Large-Scale Synthesis: Development of GSK8175 for the Treatment of Hepatitis C Virus Infection Andrew J. Peat and Shiping Xie
Editors' Biographies
Author Index
Subject Index
| Erscheinungsdatum | 24.08.2020 |
|---|---|
| Reihe/Serie | ACS Symposium Series |
| Verlagsort | New York |
| Sprache | englisch |
| Maße | 183 x 261 mm |
| Gewicht | 1004 g |
| Themenwelt | Naturwissenschaften ► Biologie ► Biochemie |
| Naturwissenschaften ► Chemie ► Analytische Chemie | |
| Naturwissenschaften ► Chemie ► Organische Chemie | |
| ISBN-10 | 0-8412-3432-9 / 0841234329 |
| ISBN-13 | 978-0-8412-3432-1 / 9780841234321 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
